Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy
Jazyk angličtina Země Řecko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
24596349
PII: 34/3/1115
Knihovny.cz E-zdroje
- Klíčová slova
- Breast cancer, review, targeted therapy, tumor-infiltrating lymphocytes,
- MeSH
- lidé MeSH
- nádory prsu diagnóza imunologie terapie MeSH
- neoadjuvantní terapie * MeSH
- prognóza MeSH
- tumor infiltrující lymfocyty imunologie patologie MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Despite the progress of tailored therapeutic strategies in patients with breast cancer, there is an unmet medical need for additional biomarkers that would guide therapy, including the administration of targeted agents. It has been demonstrated that the presence of tumor-infiltrating lymphocytes (TILs) is associated with prognosis in patients with early breast cancer. Moreover, TIL counts were shown to predict outcome of neoadjuvant chemotherapy. The neoadjuvant setting is increasingly used to assess the efficacy of new systemic therapies, and TILs are promising as a biomarker reflecting the immune response to tumor. Future studies should investigate on the integration of TILs as predictive biomarkers in patients treated with targeted- agents.
Trends in peritoneal surface malignancies: evidence from a Czech nationwide population-based study
Neopterin as a biomarker of immune response in cancer patients
